Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.00 Average Target Price from Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been assigned an average recommendation of "Hold" from the six analysts that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.00.

Several research analysts have weighed in on the company. Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating for the company in a report on Monday, June 16th. Finally, Leerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at $27,000. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at about $36,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the period. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Down 6.9%

RXRX traded down $0.37 during trading hours on Tuesday, reaching $5.03. The company's stock had a trading volume of 43,925,455 shares, compared to its average volume of 15,759,434. The business's 50-day moving average is $4.89 and its 200-day moving average is $6.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The stock has a market cap of $2.04 billion, a PE ratio of -2.84 and a beta of 0.84. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the company posted ($0.39) EPS. Recursion Pharmaceuticals's revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.